메뉴 건너뛰기




Volumn 20, Issue 6, 2015, Pages 1102-1109

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer

(11)  Inoue, Kenichi a   Kuroi, Katsumasa b   Shimizu, Satoru c   Rai, Yoshiaki d   Aogi, Kenjiro e   Masuda, Norikazu f   Nakayama, Takahiro g,h   Iwata, Hiroji i   Nishimura, Yuichiro j   Armour, Alison k   Sasaki, Yasutsuna l,m  


Author keywords

HER2; Lapatinib; Metastatic breast cancer; Paclitaxel

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEMOGLOBIN; LAPATINIB; PACLITAXEL; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

EID: 84948719874     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-015-0832-5     Document Type: Article
Times cited : (8)

References (20)
  • 1
    • 66249091930 scopus 로고    scopus 로고
    • The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine
    • COI: 1:CAS:528:DC%2BD1MXlvFOhtLw%3D, PID: 19346299
    • Ross JS, Slodkowska EA, Symmans WF et al (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320–368
    • (2009) Oncologist , vol.14 , pp. 320-368
    • Ross, J.S.1    Slodkowska, E.A.2    Symmans, W.F.3
  • 2
    • 26844457534 scopus 로고    scopus 로고
    • The distinctive nature of HER2 positive breast cancer
    • COI: 1:CAS:528:DC%2BD2MXhtFahsLjM, PID: 16236735
    • Burstein HJ, Winer EP (2005) The distinctive nature of HER2 positive breast cancer. N Engl J Med 353:1652–1654
    • (2005) N Engl J Med , vol.353 , pp. 1652-1654
    • Burstein, H.J.1    Winer, E.P.2
  • 3
    • 84905842097 scopus 로고    scopus 로고
    • Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: American Society of Clinical Oncology clinical practice guideline
    • COI: 1:CAS:528:DC%2BC2cXhtlOmtrjL, PID: 24799465
    • Giordano SH, Temin S, Kirshner JJ et al (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2078–2099
    • (2014) J Clin Oncol , vol.32 , pp. 2078-2099
    • Giordano, S.H.1    Temin, S.2    Kirshner, J.J.3
  • 4
    • 84963547999 scopus 로고    scopus 로고
    • Clinical practice guidelines in oncology. Breast cancer
    • National comprehensive cancer network (2014) Clinical practice guidelines in oncology. Breast cancer. Version 3
    • (2014) Version , pp. 3
  • 5
    • 84948716706 scopus 로고    scopus 로고
    • Evidence based breast cancer diagnostic guideline. Japanese Breast Cancer Society, editors. 1 Medicinal Therapy. 2013 version
    • Kanehara Shuppan, Tokyo
    • Japanese Breast Cancer Society (2013) Evidence based breast cancer diagnostic guideline. Japanese Breast Cancer Society, editors. 1 Medicinal Therapy. 2013 version. Tokyo: Kanehara Shuppan, Tokyo
    • (2013) Tokyo
  • 6
    • 0038010542 scopus 로고    scopus 로고
    • Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
    • PID: 12784331
    • Bendell JC, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977
    • (2003) Cancer , vol.97 , pp. 2972-2977
    • Bendell, J.C.1    Domchek, S.M.2    Burstein, H.J.3
  • 7
    • 4344691784 scopus 로고    scopus 로고
    • Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
    • COI: 1:CAS:528:DC%2BD2cXmsVCgs7k%3D, PID: 15266327
    • Clayton AJ, Danson S, Jolly S et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639–643
    • (2004) Br J Cancer , vol.91 , pp. 639-643
    • Clayton, A.J.1    Danson, S.2    Jolly, S.3
  • 8
    • 34250174543 scopus 로고    scopus 로고
    • Brain metastases: the HER2 paradigm
    • COI: 1:CAS:528:DC%2BD2sXivV2gtro%3D, PID: 17363517
    • Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13:1648–1655
    • (2007) Clin Cancer Res , vol.13 , pp. 1648-1655
    • Lin, N.U.1    Winer, E.P.2
  • 9
    • 33646372698 scopus 로고    scopus 로고
    • Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer
    • COI: 1:STN:280:DC%2BD28zptVCqtA%3D%3D, PID: 16026983
    • Stemmler HJ, Kahlert S, Siekiera W et al (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15:219–225
    • (2006) Breast , vol.15 , pp. 219-225
    • Stemmler, H.J.1    Kahlert, S.2    Siekiera, W.3
  • 10
    • 33645104239 scopus 로고    scopus 로고
    • Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab
    • COI: 1:CAS:528:DC%2BD28Xis1Cit7c%3D, PID: 16546866
    • Yau T, Swanton C, Chua S et al (2006) Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45:196–201
    • (2006) Acta Oncol , vol.45 , pp. 196-201
    • Yau, T.1    Swanton, C.2    Chua, S.3
  • 11
    • 84871713793 scopus 로고    scopus 로고
    • Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
    • PID: 23084121
    • Nielsen DL, Kumler I, Palshof AE et al (2013) Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 22:1–12
    • (2013) Breast , vol.22 , pp. 1-12
    • Nielsen, D.L.1    Kumler, I.2    Palshof, A.E.3
  • 12
    • 33845886440 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    • COI: 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D, PID: 17192538
    • Geyer C, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743
    • (2006) N Engl J Med , vol.355 , pp. 2733-2743
    • Geyer, C.1    Forster, J.2    Lindquist, D.3
  • 13
    • 42949112556 scopus 로고    scopus 로고
    • Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2–positive breast cancer
    • COI: 1:CAS:528:DC%2BD1cXlvFaqs7o%3D, PID: 18421051
    • Lin NU, Carey LA, Liu MC et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol 26:1993–1999
    • (2008) J Clin Oncol , vol.26 , pp. 1993-1999
    • Lin, N.U.1    Carey, L.A.2    Liu, M.C.3
  • 14
    • 21244449472 scopus 로고    scopus 로고
    • A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009)
    • Jones SF, Hainsworth JD, Spigel DR, et al (2004) A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009). J Clin Oncol 22(14S): (Abstract 2083)
    • (2004) J Clin Oncol , vol.22 , Issue.14S
    • Jones, S.F.1    Hainsworth, J.D.2    Spigel, D.R.3
  • 15
    • 57149096463 scopus 로고    scopus 로고
    • Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
    • PID: 18955454
    • Di Leo A, Gomez HL, Aziz Z et al (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544–5552
    • (2008) J Clin Oncol , vol.26 , pp. 5544-5552
    • Di Leo, A.1    Gomez, H.L.2    Aziz, Z.3
  • 16
    • 84880452171 scopus 로고    scopus 로고
    • Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2–overexpressing metastatic breast cancer
    • COI: 1:CAS:528:DC%2BC3sXhtVajtbvE, PID: 23509322
    • Guan Z, Xu B, DeSilvio ML et al (2013) Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2–overexpressing metastatic breast cancer. J Clin Oncol 31:1947–1953
    • (2013) J Clin Oncol , vol.31 , pp. 1947-1953
    • Guan, Z.1    Xu, B.2    DeSilvio, M.L.3
  • 17
    • 84866536687 scopus 로고    scopus 로고
    • Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2 + metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919
    • Gelmon KA, Boyle F, Kaufman B, et al (2012) Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2 + metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 30 (suppl):LBA671
    • (2012) J Clin Oncol 30 (suppl):LBA671
    • Gelmon, K.A.1    Boyle, F.2    Kaufman, B.3
  • 18
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • COI: 1:STN:280:DC%2BD3c7it1Gitg%3D%3D, PID: 10655437
    • Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 19
    • 84905566147 scopus 로고    scopus 로고
    • Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study
    • COI: 1:CAS:528:DC%2BC2cXhtlOmtrjO, PID: 24868024
    • Satoh T, Xu RH, Chung HC et al (2014) Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J Clin Oncol 32(19):2039–2049
    • (2014) J Clin Oncol , vol.32 , Issue.19 , pp. 2039-2049
    • Satoh, T.1    Xu, R.H.2    Chung, H.C.3
  • 20
    • 84862914692 scopus 로고    scopus 로고
    • Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
    • COI: 1:CAS:528:DC%2BC38XhtFSlt7Y%3D, PID: 22149875
    • Baselga J, Cortes J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119
    • (2012) N Engl J Med , vol.366 , pp. 109-119
    • Baselga, J.1    Cortes, J.2    Kim, S.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.